Lamiss Mohamed Abd Elaziz
Tanta University,Egypt
Title: Survivin as prognostic and predictive factor in patients treated with gemcitabine, dexamethasone, and cisplatin for relapsed or refractory aggressive NHL
Biography
Biography: Lamiss Mohamed Abd Elaziz
Abstract
The prognosis of relapsed or refractory aggressive non-Hodgkin’s lymphoma (NHL) after frontline therapy remains poor. The development of more effective and less toxic salvage regimens remains a major challenge. Survivin is a member of the family of inhibitors of apoptosis, and survivin was associated with short survival and bad prognosis. This study was to evaluate the efficacy of GDP regimen on relapsed or refractory aggressive NHL and various prognostic factors with special emphasis on survivin. Material and Methods: Forty-six patients with relapsed and refractory NHL, intermediate or high-grade NHL (Revised European American Lymphoma Classification), who received at least one regimen were enrolled into this study, which was carried out at oncology Department, , Tanta University from July 2012 to July 2014. The patients were treated with GDP regimen every 3 weeks. The efficacy and adverse events were evaluated according to the WHO criteria. Results The overall response rate was 58.7 %. The 24-month overall survival was 50.8 %. Survivin is associated with low overall response and shorter overall survival. The present schedule of GDP showed modest efficacy and mild toxicity in patients with relapsed or refractory aggressive NHL.
